Advertisement
BHVN vs STOK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a StrongBuy and STOK is a Buy.
BHVN in upward trend: price rose above 50-day moving average on October 22, 2026
BHVN moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BHVN as a result. In 86 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for BHVN just turned positive on October 21, 2026. Looking at past instances where BHVN's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
The 10-day moving average for BHVN crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +7.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where BHVN advanced for three days, in 200 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for BHVN moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 21 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BHVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
BHVN broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BHVN entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. BHVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BHVN's P/B Ratio (192.914) is very high in comparison to the industry average of (3.051). P/E Ratio (-3.431) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BHVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
STOK in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 13, 2026
STOK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 28 cases where STOK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STOK's RSI Oscillator exited the oversold zone, 23 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on STOK as a result. In 68 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for STOK just turned positive on October 15, 2026. Looking at past instances where STOK's MACD turned positive, the stock continued to rise in 41 of 47 cases over the following month. The odds of a continued upward trend are 87%.
Following a +2.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where STOK advanced for three days, in 271 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STOK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for STOK entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.040) is normal, around the industry mean (3.051). P/E Ratio (-7.962) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (63.291) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. STOK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
BHVN | STOK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 33 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 87 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 38 | 60 | |
P/E GROWTH RATING 1..100 | 50 | 98 | |
SEASONALITY SCORE 1..100 | 50 | 24 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STOK's Valuation (33) in the null industry is somewhat better than the same rating for BHVN (98) in the Pharmaceuticals Major industry. This means that STOK’s stock grew somewhat faster than BHVN’s over the last 12 months.
STOK's Profit vs Risk Rating (87) in the null industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to BHVN’s over the last 12 months.
STOK's SMR Rating (98) in the null industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to BHVN’s over the last 12 months.
BHVN's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as STOK (60) in the null industry. This means that BHVN’s stock grew similarly to STOK’s over the last 12 months.
BHVN's P/E Growth Rating (50) in the Pharmaceuticals Major industry is somewhat better than the same rating for STOK (98) in the null industry. This means that BHVN’s stock grew somewhat faster than STOK’s over the last 12 months.
| BHVN | STOK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 72% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 74% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 82% |
| Advances ODDS (%) | 6 days ago 75% | 1 day ago 89% |
| Declines ODDS (%) | 2 days ago 80% | 5 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BHVN’s FA Score shows that 0 FA rating(s) are green while STOK’s FA Score has 1 green FA rating(s).
- BHVN’s FA Score: 0 green, 5 red.
- STOK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BHVN’s TA Score shows that 5 TA indicator(s) are bullish while STOK’s TA Score has 5 bullish TA indicator(s).
- BHVN’s TA Score: 5 bullish, 5 bearish.
- STOK’s TA Score: 5 bullish, 3 bearish.
Price Growth
BHVN (@Biotechnology) experienced а +2.09% price change this week, while STOK (@Biotechnology) price change was +3.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -12.05%, and the average quarterly price growth was -17.02%.
Reported Earning Dates
BHVN is expected to report earnings on Mar 08, 2027.
STOK is expected to report earnings on Mar 16, 2027.
Industries' Descriptions
@Biotechnology (-2.09% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
STOK and
Correlation & Price change
A.I.dvisor indicates that over the last year, STOK has been loosely correlated with TSHA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then TSHA could also see price increases.
| Ticker / NAME | Correlation To STOK | 1D Price Change % | ||
|---|---|---|---|---|
| STOK | 100% | +1.93% | ||
| TSHA - STOK | 52% Loosely correlated | +2.25% | ||
| RCKT - STOK | 51% Loosely correlated | +1.62% | ||
| SLDB - STOK | 49% Loosely correlated | +4.67% | ||
| QTTB - STOK | 49% Loosely correlated | +0.57% | ||
| DYN - STOK | 48% Loosely correlated | +4.34% | ||
More | ||||